Company Profile

Nichi-Asia Life Science Sdn. Bhd (NALS) , a Malaysian Biotechnology company with Japanese Technology was incorporated on 28th August 2007 and was awarded the Bionexus Status on 16th October 2008 . NALS built a GMP facility which is named as Nichi-Asia Centre for Stem Cells and Regenerative Medicine (NiSCELL - The Stem Cell Lab).Ministry of Health (MOH) has approved NALS (Certificate No:931005-00005-07, on 28th August 2008) for :

1. Isolation, Processing and Expansion of Peripheral Blood for Autologous Immune- Enhancement Treatment of Cancers.

2.Isolation, Processing and Expansion of Peripheral Blood and Bone Marrow for Stem Cell Treatment of Various Diseases.

3.Anti Aging Therapy.

NiSCELL is Malaysia’s first GMP facility dedicated to process Autologous Immune Cells for the treatment of Cancers by Immune Enhancement, (Immuno Therapy), which is the fourth scientific modality for the treatment of CANCERS, using patients own NK cells and T-Lymphocytes. NiSCELL also provides facilities for Autologous Stem Cell Therapy for:
1. Cirrhosis of the Liver,
2. Ischemic Heart Diseases,
3. Chronic Limb Ischemia,
4. Spinal Cord Injuries and others.

Our core strength is the possession of technology and materials, all patented for isolation ,processing, expansion and preservation of clinically usable stem cells, progenitor cells, precursor cells as well as mature cells. We are committed to the highest international standards for ethics and scientific values. We have the exclusive rights to operate offices in Malaysia, Singapore, Indonesia and Brunei. However patients from any part of the globe can visit Malaysia for these treatments. NiSCELL will focus on providing facilities to Doctors and Hospitals to “Regenerate health with Immunotherapy and Stem Cells”.